HRS 2024: CCM® Therapy for Symptomatic Heart Failure: When CRT Isn't an Option
This sponsored Rhythm Theatre from HRS 2024 will explain what Cardiac Contractility Modulation therapy is, how it works, and the expected outcomes when utilizing this treatment for HF in NYHA Class III patients who remain symptomatic despite guideline directed medical therapy. Dr. Jagmeet Singh discusses the challenges that continue to exist in the treatment of heart failure and the unmet needs the provider community must face together. (0 - 12:00) Dr. Sameer Jamal discussed the importance of collaboration and discussion with colleagues and shares three of his own patient experiences. (13:20 - 25:57) Dr. Niraj Varma introduces the Integra-D IDE Trial design, inclusion criteria, and current status of the trial implants. CCM-D is an investigational device in clinical trials that has both CCM® and defibrillator capabilities. (26:00 - 40:40) Dr. Rami Kahwash discusses the importance of screening patients earlier for device therapy instead of waiting until patients decompensate. The concept of introducing both device therapy and GDMT together is discussed and how to identify appropriate candidates in patients with limited options available to improve their symptoms and quality of life. (40:43 -56:09)
Login to view comments.
Click here to Login
